BioSpace News Archive

Hyperfine (Nasdaq: HYPR), the creator of Swoop®, the world’s first FDA-cleared portable MRI system™, today announced that management will be presenting at the upcoming 2022 Jefferies Global Healthcare Conference in New York, New York.

Servier, today announced that the U.S. Food and Drug Administration (FDA) approved TIBSOVO® (ivosidenib tablets) in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® and J-Plasma® in surgical markets, announced today that management will participate in the following upcoming investor conferences.

Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced that members of the management team will participate in the upcoming 19th Annual Craig-Hallum Institutional Investor Conference on June 1st, 2022.

The global Synthetic Biology market size is expected to be worth around US$ 40.97 billion by 2030, according to a new report by Vision Research Reports.

According to Report, the global cell culture market size is expected to reach US$ 38 billion by 2030 and is poised to grow at a noteworthy CAGR of 12.5% from 2021 to 2030.

According to Latest Study, the global analgesics market size was valued at US$ 26.7 billion in 2020 and is projected to reach US$ 50.7 billion by 2030, growing at a CAGR of 6.6% from 2021 to 2030.

The global electrocardiograph (ecg) market is growing at a registered at a CAGR of 8.3% from 2021 to 2030 and is projected to reach around US$ 18.4 billion by 2030.

The global renal denervation market size was valued at $156,327.4 thousand in 2020, and is projected to reach $4,555,983.0 thousand by 2030, growing at a CAGR of 40.9% from 2021 to 2030.

The global transdermal drug delivery systems market size was accounted US$ 52,476.50 million in 2020, and is projected to garner US$ 87,322.40 million by 2030, growing at a CAGR of 5% from 2021 to 2030.